Are PAYO, TECH, CBAN Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17, 2026

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026.

ANTWERP, Belgium, 13 August 2026 – CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) will release its second quarter 2026 earnings prior to market opening on Thursday 27 August 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter. The half year report will be published on 3 September 2026.

Techne (TECH) came out with quarterly earnings of $0.52 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.53 per share a year ago.

Bio-Techne beat Wall Street estimates for fourth-quarter revenue on ​Wednesday helped by growth in ‌its research and diagnostics businesses.

MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 17, 2026.

MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter FY2026 Highlights Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?